A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
Level 5 - mechanism / opinion, no new human data
Bench and animal research with no human data
PubMed 37739806 · doi:10.1124/jpet.123.001733
What was done
Diet-induced obese and leptin-deficient (ob/ob) mice were administered SLU-PP-332, a synthetic agonist for estrogen-related receptor (ERR) alpha, beta, and gamma. Researchers assessed the compound's effects on metabolic parameters, fat mass accumulation, obesity, and insulin sensitivity.
What was found
The abstract reports no numerical values. It states that SLU-PP-332 administration increased energy expenditure and fatty acid oxidation, decreased fat mass accumulation, reduced obesity, and improved insulin sensitivity in the mouse models.
Why it matters
This study provides preclinical proof of concept that pharmacological pan-ERR activation can act as an exercise mimetic to treat obesity and metabolic dysfunction.
Limits
The study is restricted to mouse models, with no human data. The abstract provides no quantitative data, sample size (n), treatment duration, dosing details, or safety profile.
Cited by
- supports SLU-PP-332 functions as an exercise mimetic by acting as an agonist at the estrogen receptor-related receptor alpha.